AbCellera Biologics Inc. ABCL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $79.21M+243% | $75.13M+161% | $35.32M+7.2% | $32.88M-0.5% | $23.12M-35.4% | ||
| $191M+12.0% | $186.83M+11.7% | $182.81M+7.7% | $168.75M+1.2% | $170.47M+5.0% | ||
| —— | —— | —— | —— | —— | ||
| $291.17M-15.8% | $292.23M-14.9% | $296.6M-13.0% | $311.54M+3.0% | $345.65M+31.4% | ||
| -$211.96M+34.3% | -$217.11M+31.0% | -$261.28M+15.2% | -$278.66M-3.5% | -$322.53M-41.9% | ||
| -267.6%+1,128pp | -289%+803pp | -739.7%+195pp | -847.6%-32.9pp | -1,395.3%-760pp | ||
| $37.82M-66.2% | $39.51M-65.5% | $56.35M-46.8% | $79.87M-11.7% | $111.9M+91.0% | ||
| -$174.15M+17.3% | -$177.6M+11.4% | -$204.93M-1.4% | -$198.79M-11.2% | -$210.63M-24.9% | ||
| -$30.19M+29.4% | -$31.18M+16.9% | -$33.25M-26.1% | -$33.12M-29.8% | -$42.76M-96.8% | ||
| -$143.96M+14.2% | -$146.41M+10.1% | -$171.68M+2.3% | -$165.67M-8.1% | -$167.87M-14.3% | ||
| -181.7%+544pp | -194.9%+370pp | -486%+47.3pp | -503.9%-40.1pp | -726.2%-316pp | ||
| -$0.48+14.3% | -$0.49+10.9% | -$0.57+6.6% | -$0.55-1.9% | -$0.56-7.7% | ||
| -$188.32M+22.1% | -$194.97M+16.8% | -$243.13M-9.4% | -$228.84M-6.6% | -$241.66M-18.8% | ||
| -237.8%+808pp | -259.5%+553pp | -688.3%-14.1pp | -696.1%-46.7pp | -1,045.5%-477pp | ||
| -$211.96M+34.3% | -$217.11M+31.0% | -$261.28M+15.2% | -$278.66M-3.5% | -$322.53M-41.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does AbCellera Biologics Inc.'s income statement data come from?
- Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.